Design, Test, Build, Learn. Every stage is powered by proprietary AI models and validated by atomic-level Cryo-EM structural biology — closing the loop between computation and wet-lab reality. Design（设计）、Test（验证）、Build（合成）、Learn（学习）。每个环节均由自研 AI 模型驱动， 并通过冷冻电镜原子级解析进行实验验证 —— 真正打通干实验与湿实验的闭环。
Our AIDD stack spans target discovery, molecular generation, and druggability scoring — each algorithm peer-reviewed and validated against experimental endpoints. 我们的 AIDD 技术栈涵盖靶点发现、分子生成与成药性评估 —— 每个算法均已在同行评审期刊发表，并通过实验端点验证。
Network-Based Inference algorithms for target discovery. The foundational paper has 770+ citations (PLoS Comput. Biol. 2012). 基于网络的靶点推断算法族。基础论文被引 770+ 次 （PLoS Comput. Biol. 2012）。
Complex-disease target prediction engine, validated in NASH (RORγt target, 10nM lead, published in J. Med. Chem. 2025). 复杂疾病靶标预测引擎，已在 NASH（RORγt 靶点，10nM 先导物）中验证 —— 论文发表于 J. Med. Chem. 2025。
SE(3)-equivariant GNN + diffusion model for 3D molecular generation, validated on CDK2, ABL1, AKT1, PPARα. SE(3) 等变 GNN + 扩散模型的三维分子生成方法， 已在 CDK2、ABL1、AKT1、PPARα 等靶点验证。
Knowledge-graph-enhanced drug-target interaction prediction. Screened 13 Alzheimer's-related targets to discover 40 natural product hits. 知识图谱增强的药物-靶点相互作用预测。已筛选 13 个阿尔茨海默病关键靶标， 发现 40 个天然产物命中。
Open ADMET prediction platform with 2M+ uses worldwide. Benchmark-grade coverage across absorption, distribution, metabolism, excretion, and toxicity. 开放 ADMET 预测平台，全球使用量突破 200 万次。 覆盖吸收、分布、代谢、排泄与毒性全端点预测。
Druggability scoring system that ranks candidate molecules by clinical success potential. 成药性打分系统，依据临床成功潜力对候选分子进行排序。
Six modules covering linear peptides, cyclic peptides, small-molecule-to-peptide conversion, BBB-penetrating peptides, multi-target peptides, and peptide conjugates. 六大模块覆盖线性多肽、环肽、小分子转肽、跨血脑屏障多肽、多靶点多肽与多肽偶联。
Cyclic peptide design with enhanced stability and bioavailability. 环肽设计，提升稳定性与生物利用度。
BBB-penetrating peptides for CNS disease targeting — 10× penetration improvement. 跨血脑屏障多肽，用于中枢神经系统疾病 —— 穿透率提升 10 倍。
Small-molecule-to-peptide conversion with AI-guided sequence optimization. 小分子转多肽转化，通过 AI 引导序列优化。
Multi-target peptide design for complex disease polytherapy. 多靶点多肽设计，面向复杂疾病的多机制联合治疗。
Our integrated Cryo-EM pipeline captures binding modes at atomic resolution, feeding structural ground-truth back into our AI models and dramatically improving hit rate. 我们整合的冷冻电镜流水线在原子分辨率下捕获结合模式， 将结构真值反哺 AI 模型，显著提升命中率。
Pure-computation companies lack experimental validation depth. Traditional pharma lacks AI speed. GenTide's moat is the combination. 纯计算公司缺乏实验验证深度，传统药企缺乏 AI 速度。 GenTide 的护城河恰在两者的结合。
DTBL compresses the target-to-PCC timeline from the industry average of 3–4 years down to 1.5–2 years, saving ~75% of per-project R&D cost. This isn't "doing the same work faster" — it's a fundamentally different iteration speed. DTBL 将靶点到 PCC 的周期从行业平均 3–4 年压缩至 1.5–2 年， 节省单个项目约 75% 的 R&D 成本。这不是"同样的工作做快一点"， 而是从根本上改变了化合物优化的迭代速度。
Our <2.5 Å Cryo-EM pipeline provides the atomic-level structural ground truth that feeds back into AI models — closing the loop that pure-computation companies cannot close. Most AI drug discovery companies' shortfall is precisely the absence of high-quality experimental validation. 我们 <2.5 Å 的冷冻电镜管线提供原子级结合结构真值，反哺 AI 模型—— 打通了纯计算公司无法打通的闭环。大多数 AI 制药公司的短板恰恰在于 缺乏高质量的实验验证能力，导致计算预测与真实活性之间存在巨大落差。
The β2-AR anti-aging target is a GenTide-exclusive asset: 3–5 year head start, a Nature Aging mechanistic publication, proprietary p16 reporter mice HTS system, and a complete in-vivo validation loop. Competitors cannot fast-follow with money alone. β2-AR 抗衰老靶点是 GenTide 独有资产：3–5 年先发窗口，Nature Aging 机制发表， 独家 p16 报告基因小鼠 HTS 体系，以及完整的体内验证闭环。 竞争对手无法仅靠砸钱快速跟进。
Method patents on generative design models and binding-site conjugate design models. 生成式设计模型与结合位点偶联设计模型的方法专利。
Cryo-EM binding-pocket-derived Markush scaffolds, providing broad structural coverage. 通过冷冻电镜结合口袋确定的 Markush 骨架，提供宽泛的结构覆盖。
Novel linker design and site-specific conjugation process patents for AI-designed conjugates. 新型连接子设计与定点偶联工艺专利，覆盖 AI 设计偶联体。
Coverage in China, US, EU, and Japan via PCT filing with divisional applications. 20+ year protection per asset. 通过 PCT 分案策略覆盖中国 / 美国 / 欧盟 / 日本，每项资产保护期超 20 年。